RNA Therapeutics Market

RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028

Report Code: BT 8784 Sep, 2023, by marketsandmarkets.com

The global RNA therapeutics market in terms of revenue was estimated to be worth $13.7 billion in 2023 and is poised to reach $18.0 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines. On the other hand, the discontinuation/recalls of RNA therapeutic products is expected to hinder market growth. Higher progress in the development of RNA aptamer-based products is expected to offer lucrative opportunities to the market players. Contrarily, challenges associated with the manufacturing of RNA therapeutics are expected to impact the market growth to a certain extent.

Attractive Opportunities in the RNA Therapeutics Market

RNA Therapeutics Market

To know about the assumptions considered for the study, Request for Free Sample Report

RNA Therapeutics Market

Global RNA Therapeutics Market Dynamics

DRIVER: Increasing partnerships and collaborations among market players and RNA technology manufacturers

RNA therapeutics is a rapidly growing field that can revolutionize the treatment of a wide range of diseases. The rapid growth of this market has been fueled by strategic partnerships and collaborations, both among market players and RNA technology manufacturers. Partnerships and collaborations between market players accelerate the development and commercialization of RNA therapeutics. By pooling their resources and expertise, companies can share the costs and risks of drug development and gain access to new technologies and markets. For instance, in January 2022, Pfizer Inc. and Beam Therapeutics Inc. entered a four-year exclusive research collaboration focused on in vivo base editing programs aimed at three targets for rare genetic diseases of the liver, muscle, and central nervous system. This collaboration can produce novel therapeutics for patients with rare diseases by combining Beam Therapeutics's in vivo delivery technologies, which deliver base editors to target organs via messenger RNA (mRNA) and lipid nanoparticles (LNPs), with Pfizer's expertise in the development of drugs and vaccines.

RESTRAINT: Discontinuation or recalls of RNA therapeutic products

Instances of discontinuation or recalls can arise due to various reasons, including unexpected adverse effects, safety concerns, efficacy issues, or regulatory non-compliance. These events can lead to a loss of consumer and healthcare provider confidence in RNA therapeutic products, resulting in reduced demand and adoption. Furthermore, discontinuations or recalls can affect the reputation of the companies involved in the process and the broader perception of RNA therapeutics as a viable treatment avenue. Investors can also become cautious, decreasing the funding for R&D in the concerned field. Regulatory authorities can also intensify regulations, potentially resulting in more stringent approval processes.

OPPORTUNITY: Higher progress in the development of RNA aptamer-based therapeutics

RNA aptamers are single-stranded nucleic acid molecules that can bind to specific targets with high affinity and specificity. They have been investigated for a variety of therapeutic applications, including cancer, cardiovascular diseases, and infectious diseases. The progress in the development of RNA aptamer-based therapeutics is a major market opportunity for the market. This is because RNA aptamers have a number of potential advantages over traditional drug therapies. The field of RNA therapeutics has undergone a significant transformation with the emergence of RNA aptamer-based therapeutics. There are currently more pipeline products than approved products. One such example includes pegaptanib sodium (Macugen), discovered by Nexstar Pharmaceuticals, which is an anti-vascular endothelial growth factor (anti-VEGF) RNA aptamer to treat all types of neovascular age-related macular degeneration (AMD).

CHALLENGE: Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA

The progress of RNA therapeutics faces significant challenges that have led to the need for innovative solutions in their development and manufacturing. One of the primary obstacles pertains to the inherent susceptibility of exogenous RNA to rapid degradation by ubiquitous RNases present in both the environment and tissues. Another critical challenge involves effectively delivering negatively charged RNA molecules across the hydrophobic cytoplasmic membrane of target cells. Additionally, the strong immunogenicity of exogenous RNA posed a significant obstacle, leading to cell toxicity and hampering the translation of RNA into therapeutic proteins.

RNA Therapeutics Market Ecosystem

R&D is the initial stage in the value chain of the market. Extensive R&D is required to develop these products. R&D activities are divided into in-house and outsourced tasks. In-house tasks focus on critical activities that deal with fundamental analysis and the electronic interpretation of testing parameters. Prominent companies offer RNA drugs and vaccines (including companies with pipeline candidates in phase 3/ 4) and SMEs (companies with pipeline candidates in phase 1 to phase 4). End customers (pharmaceutical & biotechnology companies, academic & research institutions, and diagnostic companies) are the key stakeholders in the supply chain of the market. Investors/funders are the major influencers in the market.

The prominent players in the global RNA therapeutics market are Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Sanofi (France), Arrowhead Pharmaceuticals, Inc. (US), BioNtech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics (Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE (Germany), Sirnaomics (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma (US).

Ecosystem Analysis: RNA Therapeutics Market

RNA Therapeutics Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

The vaccines segment accounted for the largest share of the RNA therapeutics industry in 2022.

Based on product, the RNA therapeutics market is segmented into drugs and vaccines. Increasing investments in R&D, advancements in RNA synthesis and delivery technologies, and a growing understanding of RNA-based therapeutics have propelled the growth of the market. The R&D departments of the major companies have focused on new vaccines due to the increasing investments in this market. For instance, in August 2023, CureVac announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK. Moreover, in March 2022, Moderna announced it had begun its second phase 1 HIV vaccine trial. This latest phase 1 trial is a multicenter, open-label, randomized study (HVTN 302), which evaluates the safety and immunogenicity of their experimental HIV trimer mRNA vaccine (mRNA-1574).

The mRNA therapeutics is anticipated to dominate the RNA therapeutics industry through 2021-2028.

Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. mRNA therapeutics showcases a broad potential for treating diseases that necessitate protein expression, thereby offering heightened therapeutic efficacy due to its sustained translation into encoded proteins and peptides and enduring expression compared to conventional transient protein or peptide drugs. Evidently, these advantages of mRNA over DNA or protein/peptide introduce mRNA-based technology and products across various biomedical applications. Major industry players such as Moderna, Inc. (US), CureVac SE (Germany), BioNTech SE (Germany), Argos Therapeutics Inc. (US), Ethris GmbH (Germany), Arcturus Therapeutics (US), and Acuitas Therapeutics (Canada) develop novel mRNA therapy for a variety of indications.

The infectious diseases segment accounted for the largest share of the RNA therapeutics industry in 2022.

Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. Rapid developments in the RNA vaccine manufacturing capabilities have led to dominant share of the infectious diseases segment in the global market. mRNA vaccines offer a compelling alternative to traditional vaccine strategies due to their remarkable potency, rapid development capabilities, cost-effective manufacturing potential, and safe administration.

Hospitals & clinics generated the highest revenue in 2022 in the RNA therapeutics industry.

The RNA therapeutics market is segmented into hospitals, clinics, and research settings. An increase in the use of RNA-based therapeutics for the treatment of rare/genetic disorders contributes to the high share of hospitals & clinics. The growing use of RNA therapeutics across hospitals and clinics is driven by factors such as the increasing understanding and advancements of RNA-based therapeutics, the growing number of trends in personalized medicine, the increasing prevalence of chronic diseases, and the rising research investments by governments, private foundations, and industry stakeholders.

The North American RNA therapeutics industry is projected to grow at the fastest pace through the forecast period.

The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe is the largest regional market for RNA therapeutics. The US has emerged as the key revenue contributor to the North American market. The gene editing space has attracted significant investments and funding from venture capitalists, government agencies, and private entities in the US. This funding has fueled R&D efforts and the translation of gene editing technologies into commercial applications. The availability of capital has facilitated the growth of RNA therapeutic manufacturers, rendering the fastest growth to this region.

RNA Therapeutics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The global RNA therapeutics market is consolidated, with Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc.(US), and Pfizer Inc.  (US) emerging as the top 3 players of the global market. Players such as Novartis AG(Switzerland), Ionis Pharmaceuticals, Inc.(US), Sarepta Therapeutics, Inc.(US), Sanofi(France), Arrowhead Pharmaceuticals, Inc.(US), BioNTech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics(Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE  (Germany), Sirnaomics  (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma  (US) are some of the prominent players in the market.

Scope of the RNA Therapeutics Industry:

Report Metric

Details

Market Revenue in 2023

$13.7 billion

Estimated Value by 2028

$18.0 billion

Revenue Rate

Poised to grow at a CAGR of 5.6%

Market Driver

Increasing partnerships and collaborations among market players and RNA technology manufacturers

Market Opportunity

Higher progress in the development of RNA aptamer-based therapeutics

This research report categorizes the RNA therapeutics market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Vaccines
  • Drugs

By Type

  • mRNA Therapeutics
  • RNA Interference (RNAi) Therapeutics
  • Antisense Oligonucleotide (ASO) Therapeutics
  • Other Therapeutics

By Indication

  • Infectious Diseases
  • Rare Genetic Diseases/Hereditary Diseases
  • Other Indications

By End User

  • Hospitals and Clinics
  • Research Settings

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • RoE
  • Asia Pacific
    • China
    • South Korea
    • Japan
    • RoAPAC
  • Rest of the World

Recent Developments of RNA Therapeutics Industry

  • In February 2023, Moderna, Inc. received authorization from Health Canada for its COVID-19 booster vaccine, mRNA-1273.214 (SpikevaxBivalent Original/Omicron). This vaccine is designed for immunization against COVID-19 in children and adolescents between 6 to 17 years.
  • In January 2023, the US FDA granted Breakthrough Therapy Designation for Moderna’s investigational mRNA vaccine candidate—mRNA-1345. This vaccine was developed to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older.
  • In September 2022, Alnylam Pharmaceuticals, Inc. received marketing authorization from the European Commission for its RNAi therapy—AMVUTTRA. This treatment is developed for adult patients with stage 1 or stage 2 polyneuropathy, which is hereditary transthyretin-mediated (hATTR).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

`TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 24)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 RESEARCH LIMITATIONS 
    1.6 STAKEHOLDERS 
           1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET
 
2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 RNA THERAPEUTICS INDUSTRY SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTION 
          FIGURE 6 MARKET (SUPPLY SIDE): CAGR PROJECTIONS
          FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: MARKET
    2.4 MARKET ESTIMATION AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 IMPACT OF ECONOMIC RECESSION ON MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 38)
    FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 REGIONAL SNAPSHOT: MARKET
 
4 PREMIUM INSIGHTS (Page No. - 42)
    4.1 RNA THERAPEUTICS MARKET OVERVIEW 
          FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET SHARE, BY PRODUCT AND COUNTRY (2022) 
          FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 NORTH AMERICA: MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 
          FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 44)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET
          TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS INDUSTRY
           5.2.1 DRIVERS
                    5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers
                    5.2.1.2 Increasing number of novel modalities for RNA therapeutics
                    5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines
           5.2.2 RESTRAINTS
                    5.2.2.1 Discontinuation or recalls of RNA therapeutic products
                                TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics
                                TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT
           5.2.4 CHALLENGES
                    5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA
    5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING) 
           5.3.1 PARAMETERS OF MANUFACTURING
           5.3.2 CIRCULAR RNA ENGINEERING
    5.4 PIPELINE ANALYSIS 
FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022
           5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5)
                    5.4.1.1 Moderna, Inc.
                                TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC.
                    5.4.1.2 Pfizer, Inc.
                                TABLE 8 PIPELINE CANDIDATES OF PFIZER INC.
                    5.4.1.3 Alnylam Pharmaceuticals, Inc.
                                TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC.
                    5.4.1.4 Novartis AG
                                TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG
                    5.4.1.5 Ionis Pharmaceuticals, Inc.
                                TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC.
    5.5 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 12 PORTER’S FIVE FORCES ANALYSIS: MARKET
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 THREAT OF SUBSTITUTES
           5.5.3 BARGAINING POWER OF BUYERS
           5.5.4 BARGAINING POWER OF SUPPLIERS
           5.5.5 INTENSITY OF COMPETITIVE RIVALRY
    5.6 REGULATORY ANALYSIS 
          TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.7 VALUE CHAIN ANALYSIS 
          FIGURE 19 VALUE CHAIN ANALYSIS OF MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
    5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS
           5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES
                    FIGURE 22 KEY BUYING CRITERIA FOR END USERS
    5.10 PRICING ANALYSIS 
           5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT
                     TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION
           5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS
    5.11 KEY CONFERENCES AND EVENTS (2023–2024) 
           TABLE 18 KEY CONFERENCES AND EVENTS IN MARKET (2023–2024)
    5.12 ECOSYSTEM MARKET MAP 
 
6 RNA THERAPEUTICS MARKET, BY PRODUCT (Page No. - 65)
    6.1 INTRODUCTION 
          TABLE 19 RNA THERAPEUTICS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 VACCINES 
           6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET
                    TABLE 20 MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 21 NORTH AMERICA: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 EUROPE: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 DRUGS 
           6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET
                    TABLE 24 MARKET FOR DRUGS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 25 NORTH AMERICA: MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 EUROPE: MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 RNA THERAPEUTICS MARKET, BY TYPE (Page No. - 70)
    7.1 INTRODUCTION 
          TABLE 28 RNA THERAPEUTICS INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    7.2 MRNA THERAPEUTICS 
           7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET
                    TABLE 29 MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 30 NORTH AMERICA: MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 EUROPE: MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS 
           7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET
                    TABLE 33 MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 34 NORTH AMERICA: MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 EUROPE: MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS 
           7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
                    TABLE 37 MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 38 NORTH AMERICA: MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 EUROPE: MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 OTHER THERAPEUTICS 
 
8 RNA THERAPEUTICS MARKET, BY INDICATION (Page No. - 79)
    8.1 INTRODUCTION 
          TABLE 41 RNA THERAPEUTICS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
    8.2 INFECTIOUS DISEASES 
           8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET
                    TABLE 42 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 43 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 44 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 45 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 RARE GENETIC/HEREDITARY DISEASES 
           8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
                    TABLE 46 MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 47 NORTH AMERICA: MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 EUROPE: MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 ASIA PACIFIC: MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER INDICATIONS 
          TABLE 50 MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 51 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 52 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 53 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 RNA THERAPEUTICS MARKET, BY END USER (Page No. - 87)
    9.1 INTRODUCTION 
          TABLE 54 RNA THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 HOSPITALS AND CLINICS 
           9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET
                    TABLE 55 MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 56 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 RESEARCH SETTINGS 
           9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH
                    TABLE 59 MARKET FOR RESEARCH SETTINGS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 60 NORTH AMERICA: MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 EUROPE: MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 RNA THERAPEUTICS MARKET, BY REGION (Page No. - 93)
     10.1 INTRODUCTION 
             TABLE 63 RNA THERAPEUTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT
             TABLE 64 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 65 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 66 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 67 NORTH AMERICA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 68 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 NORTH AMERICA: RECESSION IMPACT
             10.2.2 US
                        10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market
                                      TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA
                                      TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 71 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 72 US: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 73 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Increasing government initiatives and investments for life science research to drive market
                                      TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 75 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 76 CANADA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 77 CANADA: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 79 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 80 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 81 EUROPE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 82 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 EUROPE: RECESSION IMPACT
             10.3.2 GERMANY
                        10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market
                                      TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 84 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 85 GERMANY: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 86 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market
                                      TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 88 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 89 FRANCE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 90 FRANCE: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 UK
                        10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market
                                      TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 92 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 93 UK: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 94 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 REST OF EUROPE
                        TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 96 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 97 REST OF EUROPE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                        TABLE 98 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT
             TABLE 99 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 100 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 101 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 102 ASIA PACIFIC: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
             10.4.2 JAPAN
                        10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market
                                      TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 105 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 106 JAPAN: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 107 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market
                                      TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 109 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 110 CHINA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 111 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market
                                      TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 113 SOUTH KOREA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 114 SOUTH KOREA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 115 SOUTH KOREA: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 117 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 118 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                        TABLE 119 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 REST OF THE WORLD 
             TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 121 REST OF THE WORLD: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 122 REST OF THE WORLD: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 125)
     11.1 OVERVIEW 
     11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET 
             FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS INDUSTRY, 2021–2023
     11.3 MARKET SHARE ANALYSIS 
             FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS INDUSTRY, 2022
             TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS INDUSTRY
     11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS INDUSTRY, 2020–2022
     11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: MARKET, 2022
     11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 DYNAMIC COMPANIES
             11.6.4 RESPONSIVE COMPANIES
                        FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: MARKET, 2022
     11.7 COMPETITIVE BENCHMARKING 
             TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: MARKET
     11.8 COMPETITIVE SCENARIOS AND TRENDS 
             11.8.1 KEY PRODUCT APPROVALS
                        TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021–AUGUST 2023
             11.8.2 KEY DEALS
                        TABLE 127 KEY DEALS, JANUARY 2021–AUGUST 2023
             11.8.3 OTHER KEY DEVELOPMENTS
                        TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021–AUGUST 2023
 
12 COMPANY PROFILES (Page No. - 137)
(Business overview, Products offered, Recent Developments, MNM view)*
     12.1 KEY PLAYERS 
             12.1.1 MODERNA, INC.
                        TABLE 129 MODERNA, INC.: COMPANY OVERVIEW
                        FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022)
             12.1.2 ALNYLAM PHARMACEUTICALS, INC.
                        TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
                        FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
             12.1.3 NOVARTIS AG
                        TABLE 131 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022)
             12.1.4 IONIS PHARMACEUTICALS, INC.
                        TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
                        FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
             12.1.5 SAREPTA THERAPEUTICS, INC.
                        TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
                        FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022)
             12.1.6 SANOFI
                        TABLE 134 SANOFI: COMPANY OVERVIEW
                        FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022)
             12.1.7 PFIZER INC.
                        TABLE 135 PFIZER INC.: COMPANY OVERVIEW
                        FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022)
     12.2 OTHER PLAYERS 
             12.2.1 ARROWHEAD PHARMACEUTICALS, INC.
             12.2.2 BIONTECH SE
             12.2.3 ORNA THERAPEUTICS
             12.2.4 CRISPR THERAPEUTICS
             12.2.5 SILENCE THERAPEUTICS
             12.2.6 ASTELLAS PHARMA INC.
             12.2.7 CUREVAC SE
             12.2.8 SIRNAOMICS
             12.2.9 ARCTURUS THERAPEUTICS, INC.
             12.2.10 ARBUTUS BIOPHARMA
 
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 166)
     13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.2 CUSTOMIZATION OPTIONS 
     13.3 RELATED REPORTS 
     13.4 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the RNA therapeutics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the gene editing market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), US Food and Drug Administration (US FDA), the World Health Organization (WHO), the European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), RNA Society (US), European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM), Vaccines Europe, and Central Drugs Standard Control Organization (India). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global RNA therapeutics market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

RNA Therapeutics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the RNA therapeutics market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the RNA therapeutics market and other dependent submarkets. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

RNA Therapeutics Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the RNA therapeutics industry.

Market Definition

RNA therapeutics uses both coding RNA (such as mRNA) and non-coding RNAs, which include small interfering RNAs (siRNA), aptamers, antisense oligonucleotides (ASO), ribozymes, and clustered regularly interspaced short palindromic repeats-CRISPR-associated (CRISPR/Cas) endonuclease to target proteins and DNA. RNA therapeutics have diverse abilities to target the desired protein/gene, and the ongoing research in RNA modification and delivery systems has helped in developing unique RNA-based formulations. As of 2022, the use of RNA therapeutics is approved for indications such as COVID-19, hemophilia A and B, cholesterol reduction, spinal muscular atrophy (SMA), polyneuropathy of hereditary transthyretin-mediated amyloidosis-(ATTR), and familial chylomicronaemia syndrome (FCS).

Stakeholders

  • RNA drugs and vaccine product manufacturers
  • Suppliers and distributors of vaccine manufacturing systems and consumables
  • Contract manufacturing organizations
  • Pharmaceutical and biotechnology companies
  • Research centers and medical colleges
  • Contract research organizations
  • Government associations and research institutes
  • Healthcare associations/institutes
  • Regulatory authorities
  • Business research firms

Report Objectives

  • To define, describe, and forecast the RNA therapeutics market based on product, type, end-user, and region
  • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall RNA therapeutics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), and Rest of the World (ROW)
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
  • To track and analyze competitive developments, such as product launches, partnerships, collaborations, agreements, and acquisitions, in the RNA therapeutics market
  • Micromarkets are the further segments and subsegments of the RNA therapeutics market.
  • Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Company Information: Detailed analysis and profiling of additional market players (up to five)
  • Geographic Analysis:  Further breakdown of the RoW RNA therapeutics market, by region (Latin America & Middle East). Further breakdown of the RoAPAC, RoE RNA therapeutics market, by country.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 8784
Published ON
Sep, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the RNA Therapeutics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback